# Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

> **NCT02337829** · PHASE2 · COMPLETED · sponsor: **Acerta Pharma BV** · enrollment: 48 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Acalabrutinib (Arm A)
- **DRUG:** Acalabrutinib (Arm B)

## Key facts

- **NCT ID:** NCT02337829
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-12
- **Primary completion:** 2020-06-26
- **Final completion:** 2025-10-31
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2026-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02337829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02337829, "Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02337829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*